Bebtelovimab Biosimilar - Research Grade

Out of stock
Only %1 left
SKU
ICH5377-10mg
Add to Compare

Bebtelovimab Biosimilar - Research Grade

Endotoxin
≤ 1.0 EU/mg as determined by the LAL method
Purity
>90% by SDS-PAGE
Species Reactivity
Human
Target
Severe acute respiratory syndrome coronavirus 2
Concentration
>1mg/ml
Isotype
IgG1 - lambda2
Host
CHO Cells
Sequence
https://www.imgt.org/mAb-DB/
Buffer
ICH3002
Shipping Conditions
Blue ice
Background
The SARS-CoV-2 spike protein mediates viral entry and remains a key antigen for neutralization and immunology research. This antibody is an unconjugated, non-therapeutic analog of bebtelovimab, a human IgG1-lambda recombinant monoclonal intended for research use only (RUO). It is provided in an ultra-pure, low-endotoxin format built to in vivo standards and manufactured in scalable milligram-to-gram quantities to support heavy-usage and high-throughput virology workflows. Applications include functional and neutralization assays, antigen-binding characterization, in vitro screening and preclinical models examining SARS-CoV-2 spike engagement, all with reliable lot-to-lot consistency.
Purification Method
This monoclonal antibody was purified using Protein A
Formulation
Sterile, preservative-free, solution in PBS. BSA and Azide free.
Storage
This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.
Applications
Functional Assays
Application Notes
This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.
Use
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
Delivery Time
3-4 weeks
Faq (q&a)

Q: Is the Bebtelovimab biosimilar available in gram quantities?

A: Yes — it is manufactured in scalable milligram to gram quantities to support bulk and high-throughput preclinical experiments.


Q: Is this research-grade Bebtelovimab biosimilar suitable for in vivo studies?

A: Yes, it is supplied in a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).


Q: What does the Bebtelovimab biosimilar target?

A: It is a non-therapeutic research analog of Bebtelovimab that recognizes and neutralizes Severe acute respiratory syndrome coronavirus 2; for research use only.


Write Your Own Review
You're reviewing:Bebtelovimab Biosimilar - Research Grade
Your Rating
Is the Bebtelovimab biosimilar available in gram quantities?

Yes — it is manufactured in scalable milligram to gram quantities to support bulk and high-throughput preclinical experiments.

Is this research-grade Bebtelovimab biosimilar suitable for in vivo studies?

Yes, it is supplied in a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

What does the Bebtelovimab biosimilar target?

It is a non-therapeutic research analog of Bebtelovimab that recognizes and neutralizes Severe acute respiratory syndrome coronavirus 2; for research use only.

Back to Top